Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

NCT06118086 is registered in ClinicalTrials.gov with Remix Therapeutics as lead sponsor.

NCT NCT06118086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06118086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Lead sponsor
Remix Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 20, 2023
Completion date
September 30, 2027
Enrollment
125 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, metastatic adenoid cystic carcinoma, recurrent adenoid cystic carcinoma